[go: up one dir, main page]

FI3888641T3 - Kannabidiolin käyttö Doose-oireyhtymään liittyvien kohtausten hoidossa - Google Patents

Kannabidiolin käyttö Doose-oireyhtymään liittyvien kohtausten hoidossa

Info

Publication number
FI3888641T3
FI3888641T3 FIEP21166413.1T FI21166413T FI3888641T3 FI 3888641 T3 FI3888641 T3 FI 3888641T3 FI 21166413 T FI21166413 T FI 21166413T FI 3888641 T3 FI3888641 T3 FI 3888641T3
Authority
FI
Finland
Prior art keywords
cbd
seizures
cannabidiol
treatment
doose syndrome
Prior art date
Application number
FIEP21166413.1T
Other languages
English (en)
Inventor
Geoffrey Guy
Stephen Wright
Alice Mead
Orrin Devinsky
Original Assignee
Jazz Pharmaceuticals Res Uk Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jazz Pharmaceuticals Res Uk Limited filed Critical Jazz Pharmaceuticals Res Uk Limited
Application granted granted Critical
Publication of FI3888641T3 publication Critical patent/FI3888641T3/fi

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/348—Cannabaceae
    • A61K36/3482—Cannabis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Botany (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Biotechnology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)

Claims (4)

PATENTTIVAATIMUKSET
1. — Kannabidioli (CBD) käytettäväksi Doose-oireyhtymään liittyvien kohtausten hoidossa, jolloin CBD:n puhtaus on vähintään 98 % (paino/paino) CBD:tä, ja jolloin CBD annetaan 5 mg/kg/vrk ja annosta lisätään sitten 2-5 mg/kg kerrallaan enintään enimmäisannokseen 25 mg/kg/vrk asti, jolloin CBD:tä käytetään yhdessä vähintään yhden samanaikaisen epilepsialääkkeen (AED) kanssa.
2. CBD käytettäväksi patenttivaatimuksen 1 mukaisesti, jolloin CBD:tä käytetään yhdessä vähintään kahden samanaikaisen epilepsialääkkeen (AED) kanssa.
3. CBD käytettäväksi jonkin edellisen patenttivaatimuksen mukaisesti, jolloin Doose-oireyhtymään liittyvät kohtaukset ovat yksi tai useampi seuraavista myokloniset kohtaukset, poissaolokohtaukset, atoniset kohtaukset, myokloniset poissaolokohtaukset, tooniset kohtaukset ja/tai toonis-klooniset kohtaukset.
4. CBD käytettäväksi jonkin edellisen patenttivaatimuksen mukaisesti, jolloin CBD annetaan seesamiöljyä sisältävässä koostumuksessa.
FIEP21166413.1T 2014-10-14 2015-10-14 Kannabidiolin käyttö Doose-oireyhtymään liittyvien kohtausten hoidossa FI3888641T3 (fi)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB1418169.7A GB2531280A (en) 2014-10-14 2014-10-14 Use of cannabidiol in the treatment of intractable epilepsy

Publications (1)

Publication Number Publication Date
FI3888641T3 true FI3888641T3 (fi) 2025-10-16

Family

ID=52001391

Family Applications (1)

Application Number Title Priority Date Filing Date
FIEP21166413.1T FI3888641T3 (fi) 2014-10-14 2015-10-14 Kannabidiolin käyttö Doose-oireyhtymään liittyvien kohtausten hoidossa

Country Status (7)

Country Link
US (3) US20170239193A1 (fi)
EP (2) EP3888641B1 (fi)
DK (1) DK3888641T3 (fi)
ES (2) ES2880469T3 (fi)
FI (1) FI3888641T3 (fi)
GB (1) GB2531280A (fi)
WO (1) WO2016059405A1 (fi)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2487712B (en) 2011-01-04 2015-10-28 Otsuka Pharma Co Ltd Use of the phytocannabinoid cannabidiol (CBD) in combination with a standard anti-epileptic drug (SAED) in the treatment of epilepsy
GB2495118B (en) 2011-09-29 2016-05-18 Otsuka Pharma Co Ltd A pharmaceutical composition comprising the phytocannabinoids cannabidivarin (CBDV) and cannabidiol (CBD)
GB2530001B (en) 2014-06-17 2019-01-16 Gw Pharma Ltd Use of cannabidiol in the reduction of convulsive seizure frequency in treatment-resistant epilepsy
GB2531282A (en) 2014-10-14 2016-04-20 Gw Pharma Ltd Use of cannabinoids in the treatment of epilepsy
GB2531278A (en) 2014-10-14 2016-04-20 Gw Pharma Ltd Use of cannabidiol in the treatment of intractable epilepsy
GB2531281A (en) 2014-10-14 2016-04-20 Gw Pharma Ltd Use of cannabidiol in the treatment of intractable epilepsy
GB2539472A (en) 2015-06-17 2016-12-21 Gw Res Ltd Use of cannabinoids in the treatment of epilepsy
GB2541191A (en) 2015-08-10 2017-02-15 Gw Pharma Ltd Use of cannabinoids in the treatment of epilepsy
GB2548873B (en) 2016-03-31 2020-12-02 Gw Res Ltd Use of Cannabidiol in the Treatment of SturgeWeber Syndrome
GB2551986A (en) 2016-07-01 2018-01-10 Gw Res Ltd Parenteral formulations
GB2551987A (en) * 2016-07-01 2018-01-10 Gw Res Ltd Oral cannabinoid formulations
GB2553139A (en) 2016-08-25 2018-02-28 Gw Res Ltd Use of cannabinoids in the treatment of multiple myeloma
GB2557921A (en) 2016-12-16 2018-07-04 Gw Res Ltd Use of cannabinoids in the treatment of angelman syndrome
GB2559774B (en) 2017-02-17 2021-09-29 Gw Res Ltd Oral cannabinoid formulations
GB2560019A (en) 2017-02-27 2018-08-29 Gw Res Ltd Use of cannabinoids in the treatment of leukaemia
GB2564383B (en) 2017-06-23 2021-04-21 Gw Res Ltd Use of cannabidiol in the treatment of tumours assoicated with Tuberous Sclerosis Complex
GB201715919D0 (en) 2017-09-29 2017-11-15 Gw Res Ltd use of cannabinoids in the treatment of epilepsy
GB2568929A (en) 2017-12-01 2019-06-05 Gw Res Ltd Use of cannabinoids in the treatment of epilepsy
GB2569961B (en) 2018-01-03 2021-12-22 Gw Res Ltd Pharmaceutical
GB201806953D0 (en) 2018-04-27 2018-06-13 Gw Res Ltd Cannabidiol Preparations
GB2580881A (en) * 2018-11-30 2020-08-05 Gw Res Ltd Use of cannabinoids in the treatment of epilepsy
GB2581517A (en) * 2019-02-22 2020-08-26 Gw Res Ltd Use of cannabinoids in the treatment of epilepsy
GB201910389D0 (en) 2019-07-19 2019-09-04 Gw Pharma Ltd Novel compounds, methods for their manufacture, and uses thereof
GB2588576A (en) 2019-08-27 2021-05-05 Gw Res Ltd Use of cannabinoids in the treatment of dyskinesia associated with Parkinson's disease
GB201916846D0 (en) 2019-11-19 2020-01-01 Gw Res Ltd Cannabidiol-type cannabinoid compound
GB201916849D0 (en) 2019-11-19 2020-01-01 Gw Res Ltd Cannabidiol-type cannabinoid compound
GB201916977D0 (en) 2019-11-21 2020-01-08 Gw Res Ltd Cannibidol-type cannabinoid compound
GB201916974D0 (en) 2019-11-21 2020-01-08 Gw Res Ltd Cannabidol-type cannabinoid compound
GB202002754D0 (en) 2020-02-27 2020-04-15 Gw Res Ltd Methods of treating tuberous sclerosis complex with cannabidiol and everolimus
GB2597304A (en) * 2020-07-20 2022-01-26 Gw Res Ltd Use of cannabidiol in the treatment of seizures associated with shaken baby syndrome
GB2597301A (en) * 2020-07-20 2022-01-26 Gw Res Ltd Use of cannabidiol in the treatment of seizures associated with herpes simplex virus
GB2597280A (en) 2020-07-20 2022-01-26 Gw Res Ltd Use of cannabidiol in the treatment of seizures associated with auriculotemporal syndrome
GB2597302A (en) * 2020-07-20 2022-01-26 Gw Res Ltd Use of cannabidiol in the treatment of seizures associated with stroke or brain haemorrhage
GB2597285A (en) * 2020-07-20 2022-01-26 Gw Res Ltd Use of cannabidiol in the treatment of seizures associated with rare epilepsy syndromes related to genetic abnormalities
WO2022017936A1 (en) * 2020-07-20 2022-01-27 GW Research Limited Use of cannabidiol in the treatment of seizures associated with rare epilepsy syndromes related to structural abnormalities of the brain
GB2597282A (en) * 2020-07-20 2022-01-26 Gw Res Ltd Use of cannabidiol in the treatment of seizures associated with rare epilepsy syndromes related to genetic abnormalities
US11160757B1 (en) 2020-10-12 2021-11-02 GW Research Limited pH dependent release coated microparticle cannabinoid formulations
US20250241933A1 (en) * 2022-06-21 2025-07-31 Apnimed, Inc. (Delaware) Methods of treating sleep apnea with a combination of a cannabinoid and a carbonic anhydrase inhibitor
US11977085B1 (en) 2023-09-05 2024-05-07 Elan Ehrlich Date rape drug detection device and method of using same

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7705039B2 (en) * 2001-04-06 2010-04-27 The Board Of Trustees Of The University Of Illinois Method for treating sleep apnea
WO2011063164A2 (en) * 2009-11-18 2011-05-26 Steady Sleep Rx Co., Inc. Sustained release cannabinoid medicaments
BR112013012468A2 (pt) * 2010-11-18 2016-09-06 Pier Pharmaceuticals método de tratar um indivíduo com um distúrbio sensível a canabinóide, de estabelecer uma dose ideal, de tratar um indivíduo com um distúrbio de apneia do sono, e, kit
GB2530001B (en) * 2014-06-17 2019-01-16 Gw Pharma Ltd Use of cannabidiol in the reduction of convulsive seizure frequency in treatment-resistant epilepsy

Also Published As

Publication number Publication date
US20230032502A1 (en) 2023-02-02
WO2016059405A1 (en) 2016-04-21
DK3888641T3 (da) 2025-10-06
US20170239193A1 (en) 2017-08-24
EP3206680B1 (en) 2021-04-21
EP3888641A1 (en) 2021-10-06
GB201418169D0 (en) 2014-11-26
EP3888641B1 (en) 2025-09-10
EP3206680A1 (en) 2017-08-23
ES3045135T3 (en) 2025-11-27
GB2531280A (en) 2016-04-20
ES2880469T3 (es) 2021-11-24
US20240261234A1 (en) 2024-08-08

Similar Documents

Publication Publication Date Title
FI3888641T3 (fi) Kannabidiolin käyttö Doose-oireyhtymään liittyvien kohtausten hoidossa
RU2020127876A (ru) Применение каннабиноидов в лечении эпилепсии
MX386086B (es) Composicion de cannabis
WO2015159272A3 (en) Curcumin compositions and uses thereof
MX2019008337A (es) Uso de cannabinoides para el tratamiento de epilepsia.
UY37272A (es) Piridinas sustituidas con heteroarilo y métodos de uso
BR112016020618A8 (pt) oligômero antissentido, composição farmacêutica, e, uso de um oligômero antissentido
PH12015501866A1 (en) Tricyclic compounds as inhibitors of immunosuppression mediated by tryptophan metabolization
MX349027B (es) Uso del fitocannabinoide cannabidiol (cbd) en combinacion con un farmaco estandar antiepileptico (saed) en el tratamiento de la epilepsia.
CL2015002891A1 (es) Deaza-purinonas macrocíclicas para el tratamiento de infecciones virales.
CL2016000408A1 (es) Composiciones farmaceuticas que contienen diastereomeros macrolidos, metodos para su sintesis y usos terapeuticos.
CL2015002677A1 (es) Composiciones que comprenden selenio y uso de las mismas para el tratamiento y prevención de enfermedades o condiciones asociadas con la disfunción mitocondrial.
PH12020550964A1 (en) Heavy chain antibodies binding to cd22
MX2018002906A (es) Metodos de tratamiento de trastornos del desarrollo con pipradrol.
CR20180228A (es) Terapia adjunta con 25-hidroxi vitamina d y articulos de la misma
CL2016002879A1 (es) Composiciones farmacéuticas para tratar enfermedades infecciosas
WO2015079010A3 (en) Pharmaceutical composition comprising lacosamide and levetiracetam
MX2015003343A (es) Tratamiento combinado con el farmaco de interferencia de netrina-1 y el farmaco quimioterapeutico.
MX364528B (es) Witanólidos útiles para el tratamiento de enfermedades neurodegenerativas.
MX2018000872A (es) Combinaciones terapeuticas de paclitaxel oralmente administrado y un inhibidor de la bomba de p-glicoproteina (p-gp) para el tratamiento del cancer.
MX2018014129A (es) Composiciones farmaceuticas de oligomero de morfolino fosforodiamidato.
MX2018005439A (es) Compuestos oxadiazoespiricos para el tratamiento del abuso y la adiccion a las drogas.
AR105095A1 (es) Concentrado de jugo de fruta para una marinada
MD20180049A2 (ro) Compoziţie farmaceutică
WO2016072692A3 (ko) 네크록스를 유효성분으로 함유하는 점막염 예방 또는 치료용 조성물